NCT05295589View on ClinicalTrials.gov

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2022

Primary Completion Date

March 17, 2023

Study Completion Date

March 17, 2023

Conditions
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Platinum-Resistant Primary Peritoneal CarcinomaRecurrent Primary Peritoneal Endometrioid AdenocarcinomaRecurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Copanlisib Hydrochloride

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Olaparib

Given PO

DRUG

Paclitaxel

Given IV

DRUG

Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

DRUG

Topotecan Hydrochloride

Given IV

Trial Locations (5)

44195

Cleveland Clinic Foundation, Cleveland

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

73104

University of Oklahoma Health Sciences Center, Oklahoma City

80045

University of Colorado Hospital, Aurora

02905

Women and Infants Hospital, Providence

Sponsors

Collaborators (1)

NRG Oncology
All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT05295589 - Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | Biotech Hunter | Biotech Hunter